Research and Markets: This New Strategic Analysis Report "Novo Nordisk: Performance, Products, Pipeline And Potential" Provides a Complete and Critical Review of the Company.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c64451) has announced the addition of Espicom Business Intelligence's new report Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest : Performance, Products, Pipeline and Potential to their offering Novo Nordisk is a biotech-based healthcare company with a broad diabetes product portfolio. It also has a leading position in haemostasis hemostasis, haemostasis the stoppage of bleeding or cessation of the circulation of the blood; stagnation of the blood in a part of the body. Also hemostasia, haemostasia. See also: Blood and Blood Vessels Noun 1. management, growth hormone growth hormone or somatotropin (sōmăt'ətrō`pən), glycoprotein hormone released by the anterior pituitary gland that is necessary for normal skeletal growth in humans (see protein). therapy and hormone replacement therapy Hormone Replacement Therapy Definition Hormone replacement therapy (HRT) is the use of synthetic or natural female hormones to make up for the decline or lack of natural hormones produced in a woman's body. . This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. This new strategic analysis report Novo Nordisk: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Pharmaceutical company intelligence reports from us provide a full review of the company's activities together with five-year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices ap·pen·di·ces n. A plural of appendix. provide more in-depth information on financials, agreements and corporate events. Report Content EXECUTIVE SUMMARY A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis. THERAPEUTIC AREA FOCUS Key product analysis and forecasting Diabetes Care - Levemir (insulin detemir) - NovoRapid/NovoLog (insulin aspart) - NovoMix/NovoLog Mix (insulin aspart) - NovoNorm/Prandin (repaglinide) Biopharmaceuticals - NovoSeven (recombinant Factor VIIa) - Norditropin (somatropin) - Activelle/Activella (17-beta oestradiol+norethisterone acetate) - Vagifem (17-beta oestradiol) - GlucaGen (glucagon) OPERATIONAL DATA A wealth of background and detail - A full 5-year financial performance assessment - Key agreements - Infrastructure - Subsidiaries and joint ventures Novo Nordisk is a biotech-based healthcare company with the broadest diabetes product portfolio in the industry and a world leader in diabetes care. In addition, it has a leading position in haemostasis management, growth hormone therapy and hormone replacement therapy and is currently expanding into the new therapeutic areas of cancer and inflammation inflammation, reaction of the body to injury or to infectious, allergic, or chemical irritation. The symptoms are redness, swelling, heat, and pain resulting from dilation of the blood vessels in the affected part with loss of plasma and leucocytes (white blood . Its products are marketed in 179 countries. As a focused healthcare company and world leader in diabetes care, Novo Nordisk is committed to maintaining its strong position in this field, which builds on more than 80 years experience. Its diabetes strategy is based on the industry's broadest portfolio of insulin insulin, hormone secreted by the β cells of the islets of Langerhans, specific groups of cells in the pancreas. Insufficiency of insulin in the body results in diabetes. Insulin was one of the first products to be manufactured using genetic engineering. analogues and injection devices, together with cutting-edge research and a wide range of partnerships. The biopharmaceuticals business is an increasing growth driver for the company, currently fuelled by NovoSeven NovoSeven® Hematology A recombinant coagulation factor VIIa indicated for treating bleeding episodes in hemophilia A or B Pts with antibodies to coagulation factors VIII or IX . Novo Nordisk intends to build a broader biopharmaceuticals business, with new business areas focusing on immunotherapy Immunotherapy The treatment of cancer by improving the ability of a tumor-bearing individual (the host) to reject the tumor immunologically. There are molecules on the surface of tumor cells, and perhaps in their interior, that are recognized as different from in cancer and inflammation. The company already has a number of projects in early-phase development in these areas, but they are unlikely to significantly contribute to its business within the next ten years. However, to accelerate this process Novo Nordisk is establishing the technology platform and strengthening the skills base required both in-house In-house In the context of general equities, keeping an activity within the firm. For example, rather than go to the marketplace and sell a security for a client to anyone, an attempt is made to find a buyer to complete the transaction with the firm. and with partners. Novo Nordisk is working to create a culture of innovation throughout its entire organisation. It recently conducted a review of its capacity to innovate in·no·vate v. in·no·vat·ed, in·no·vat·ing, in·no·vates v.tr. To begin or introduce (something new) for or as if for the first time. v.intr. To begin or introduce something new. and as a result, a number of projects have been selected for future development. It has previously developed a new technology for prolonging the duration of insulin, which has been used in the development of the insulin analogue (electronics) analogue - (US: "analog") A description of a continuously variable signal or a circuit or device designed to handle such signals. The opposite is "discrete" or "digital". , Levemir, and liraglutide. The technology has the potential to be applicable to any biopharmaceutical compound. Novo Nordisk plans to expand its sales and marketing activities, particularly in the US and Chinese markets. Companies Mentioned: - Aradigm Corporation - Argos Therapeutics - BioStratum Incorporated - BioVisioN AG - Cephalon - Crucell NV - GlaxoSmithKline - G2 Inflammation Pty Ltd - Innate Pharma SAS - Medarex Inc - Morphotek Inc - Nastech Pharmaceutical - Neose Technologies Inc - Sangamo BioSciences Inc - Sapphire Therapeutics Inc - Scios Inc - SR Pharma plc - Takeda - Transition Therapeutics Inc - TransTech Pharma Inc - ZymoGenetics Inc For more information visit http://www.researchandmarkets.com/reports/c64451 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion